Patents by Inventor Francis G. Fang

Francis G. Fang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intermediates and methods for the synthesis of halichondrin B analogs
    Patent number: 9802953
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 31, 2017
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B
    Patent number: 9783549
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: October 10, 2017
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • STEREOCHEMICALLY DEFINED POLYPROPIONATES AND METHODS FOR MAKING AND USING THE SAME
    Publication number: 20170240560
    Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 24, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. FANG, Hyeong-Wook CHOI, Silvio CAMPAGNA, Steven MATHIEU
  • Intermediates and methods for the synthesis of halichondrin B analogs
    Patent number: 9604993
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 28, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Charles E. Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS
    Publication number: 20160376294
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Application
    Filed: June 29, 2016
    Publication date: December 29, 2016
    Inventors: Atsushi ENDO, Charles E. CHASE, Francis G. FANG
  • MACROCYCLIZATION REACTIONS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B
    Publication number: 20160264594
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: November 4, 2014
    Publication date: September 15, 2016
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • INTERMEDIATES AND METHODS FOR THE SYNTHESIS OF HALICHONDRIN B ANALOGS
    Publication number: 20160214992
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 28, 2016
    Inventors: Charles E. CHASE, Atsushi ENDO, Francis G. FANG, Jing LI
  • Compounds useful in the synthesis of halichondrin B analogs
    Patent number: 9382262
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 5, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Charles E. Chase, Francis G. Fang
  • Method for producing 5-(difluoromethyl)pyrazine-2-carboxylic acid and production intermediate thereof
    Patent number: 9227942
    Abstract: 5-(Difluoromethyl)pyrazine-2-carboxylic acid, which is a raw material for the construction of 5-(difluoromethyl)pyrazine-2-carboxamide, which is a common partial structural motif of the compound having an A? production inhibitory action or a BACE1 inhibitory action, can be industrially advantageously produced by decarboxylating 5-[carboxy(difluoro)methyl]pyrazine-2-carboxylic acid, which is obtainable from 5-chloropyrazine-2-carboxylate.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: January 5, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Kazuhiro Yoshizawa, Masayuki Omori, Yuzo Watanabe, Mitsuo Nagai, Masabumi Takahashi, Francis G. Fang
  • INTERMEDIATES AND METHODS FOR THE SYNTHESIS OF HALICHONDRIN B ANALOGS
    Publication number: 20150225415
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Application
    Filed: February 17, 2015
    Publication date: August 13, 2015
    Inventors: Charles E. CHASE, Atsushi ENDO, Francis G. FANG, Jing LI
  • COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS
    Publication number: 20150175620
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Inventors: Atsushi ENDO, Charles E. CHASE, Francis G. FANG
  • METHOD FOR PRODUCING 5-(DIFLUOROMETHYL)PYRAZINE-2-CARBOXILIC ACID AND PRODUCTION INTERMEDIATE THEREOF
    Publication number: 20150087836
    Abstract: 5-(Difluoromethyl)pyrazine-2-carboxilic acid, which is a raw material for the construction of 5-(difluoromethyl)pyrazine-2-carboxamide, which is a common partial structural motif of the compound having an A production inhibitory action or a BACE1 inhibitory action, can be industrially advantageously produced by decarboxylating 5-[carboxy(difluoro)methyl]pyrazine-2-carboxylic acid, which is obtainable from 5-chloropyrazine-2-carboxylate.
    Type: Application
    Filed: April 25, 2013
    Publication date: March 26, 2015
    Inventors: Kazuhiro Yoshizawa, Masayuki Omori, Yuzo Watanabe, Mitsuo Nagai, Masabumi Takahashi, Francis G. Fang
  • Intermediates and methods for the synthesis of halichondrin B analogs
    Patent number: 8987479
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: March 24, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Charles Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • Intermediates for the preparation of analogs of halichondrin B
    Patent number: 8975422
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 10, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, Bryan M. Lewis, Matthew Schnaderbeck
  • Compounds for preparing immunological adjuvant
    Patent number: 8962857
    Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: February 24, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, James E. Foy, Lynn Hawkins, Charles Lemelin, Andre LesCarbeau, Xiang Niu, Kuo-Ming Wu
  • Compounds useful in the synthesis of halichondrin B analogs
    Patent number: 8927597
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: January 6, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Charles E. Chase, Francis G. Fang
  • Intermediates for the preparation of analogs of halichondrin B
    Patent number: 8884031
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: November 11, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Charles E. Chase, Francis G. Fang
  • COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT
    Publication number: 20140323739
    Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.
    Type: Application
    Filed: May 5, 2014
    Publication date: October 30, 2014
    Applicant: Eisai R&D Management Co.. Ltd.
    Inventors: Francis G. Fang, James E. Foy, Lynn Hawkins, Charles Lemelin, Andre LesCarbeau, Xiang Niu, Kuo-Ming Wu
  • INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B
    Publication number: 20140221635
    Abstract: Intermediates and methods of their use in the synthesis of anslogs of halichondrin B are provided.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 7, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. FANG, Bryan M. LEWIS, Matthew SCHNADERBECK
  • Intermediates for the preparation of analogs of halichondrin B
    Patent number: RE45324
    Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: January 6, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Brian Austad, Charles E. Chase, Francis G. Fang